Drug Profile
Citrate/heparin/taurolidine - CorMedix Pharmaceuticals
Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrateLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator ND Partners
- Developer CorMedix
- Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
- Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Catheter infections
Most Recent Events
- 15 Apr 2024 Launched for Catheter infections (Prevention) in USA (unspecified route)
- 15 Apr 2024 CorMedix plans to launch DefenCath for Catheter infections (Prevention) in USA in July 1, 2024 for the outpatient setting
- 12 Mar 2024 CorMedix plans a post-approval meeting to discuss clinical pathway of DefenCath® for an expanded label with the US FDA in mid-year 2024